Bioniche Granted Patent for Oligonucleotide Technology
News Mar 17, 2006
Bioniche Life Sciences Inc. has announced that it has been granted a European patent - EP1432450 - covering the composition and use of an oligonucleotide family for the treatment of cancer entitled: "Therapeutically Useful Triethyleneglycol Cholesteryl Oligonucleotides", inventors Dr. Nigel C. Phillips, Dr. Mario C. Filion, and Dr. Andrea Herrera-Gayol.
Dr. Nigel C. Phillips, Chief Scientific Officer for Bioniche Life Sciences Inc. stated, "This patent consolidates our oligonucleotide patent portfolio. These oligonucleotides constitute a new composition family that enhances our ability to develop effective treatments for oncology indications."
"Bioniche now has technology platforms based on mycobacterial cell walls, unmodified oligonucleotides and modified oligonucleotides that have immune stimulant and anticancer activity."
"Bioniche is in a position to develop effective treatments for cancer using these unique and complementary technology platforms."
Graeme McRae, President & CEO of Bioniche Life Sciences Inc., commented, "The oligonucleotide platform is another example of Bioniche's ability to develop novel technologies."
"We plan to develop this platform through additional pre-clinical research in the immunomodulatory and anti-cancer areas and seek opportunities to partner the technology for further development."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.